Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

FDA approval for CR Bard's collagen haemostat:

This article was originally published in Clinica

Executive Summary

CR Bard's subsidiary Davol has received US FDA approval to market its Avitene Ultrafoam collagen haemostat, a collagen sponge designed to stop bleeding during surgical procedures by accelerating blood clot formation. Its uses include neurosurgery where topical haemostats are most frequently used. The sponge provides surgeons with better visibility during a surgical procedure by minimising the collection of blood, minimises the patients blood loss and prevents post-operative complications due to haemorrhage, said the Murray Hill, New Jersey-based company.

Advertisement

Topics

Advertisement
UsernamePublicRestriction

Register

MT075666

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel